Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo3 hours agoBIIB
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass., September 03, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Drave
Yahoo19 hours agoBIIB
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
BenzingayesterdayBIIB
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
YahooyesterdayBIIB
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the
BenzingayesterdayBIIB
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®
YahooyesterdayBIIB
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...
YahooyesterdayBIIB
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g
Yahoo3 days agoBIIB
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
Benzinga3 days agoBIIB
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
An Important Step Forward for Access to LEQEMBI® for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD). The final recommendation follows a r
Yahoo3 days agoBIIB
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]
Yahoo5 days agoBIIB
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo7 days agoBIIB
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Yahoo8 days agoBIIB
Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ...
Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.
Yahoo8 days agoBIIB
Veeva Systems Q2 Earnings Call Highlights
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
Yahoo8 days agoBIIB
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.
Benzinga10 days agoBIIB
Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple
Acadia (ACAD) eyes Phase 2 remlifanserin Alzheimerâs psychosis results by September/October. Learn about the risks and revenue cushion from Daybue/Nuplazid.
SeekingAlpha10 days agoBIIB
Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy for early
Benzinga11 days agoBIIB
Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?
Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 year total shareholder returns. This...
Yahoo14 days agoBIIB
What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders
In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company’s long-term profile. Next, we’ll examine how Biogen’s higher earnings guidance and advancing...
Yahoo14 days agoBIIB
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Yahoo15 days agoBIIB
Is Wall Street Bullish or Bearish on Biogen Stock?
Biogen has notably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
Yahoo15 days agoBIIB
Real Parkinson’s Disease Hope from Jupiter Neurosciences
By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.
Yahoo16 days agoBIIB
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating
Biogen (BIIB) flashes a perfect technical rating and strong breakout setup, with a proposed entry at $215.61 and defined stop.
ChartMill18 days agoBIIB
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.
Benzinga22 days agoBIIB
NovelMed Advances NM5072 for Multiple Ocular Disorders
Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan.Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in a rhesus monkey model.Phase I clinical experience: NM5072 completed a Phase I study in 48 healthy volunteers and received FDA Orphan Drug Designation for PNH.Potential extended durability: Rabbit PK/PD data
Yahoo23 days agoBIIB
Biogen (BIIB) Q2 2026 Earnings Call Transcript
Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.
Yahoo27 days agoBIIB
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
Yahoo28 days agoBIIB
Biogen Completes Acquisition of RayThera Inc.
Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program ent
Yahoo28 days agoBIIB
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.
SeekingAlphalast monthBIIB
Biogen Stock: How To Find & Own America's Greatest Opportunities
Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold.
Yahoolast monthBIIB
Mizuho Maintains Outperform on Biogen, Raises Price Target to $241
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.
Benzingalast monthBIIB